NGN Capital
37
25M
21
1.85
12
0.43
12
- Stages of investment
- Areas of investment
Summary
The leading representative office of defined VC is situated in the New York. The venture was found in North America in United States.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the NGN Capital, startups are often financed by 3i Group, Forbion Capital Partners, Neomed Management. The meaningful sponsors for the fund in investment in the same round are 3i Group, MedVenture Associates, Forbion Capital Partners. In the next rounds fund is usually obtained by Forbion Capital Partners, Arcus Ventures, 3i Group.
Besides them, we counted 6 critical employees of this fund in our database.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight OptiScan Biomedical, Aerovance, Artisan Pharma. Among the most successful fund investment fields, there are Pharmaceutical, Medical Device. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.
The important activity for fund was in 2010. The common things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 22 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this NGN Capital works on 1 percentage points more the average amount of lead investments. The fund is generally included in 2-6 deals every year. The higher amount of exits for fund were in 2016.
Investments analytics
Analytics
- Total investments
- 37
- Lead investments
- 12
- Exits
- 12
- Rounds per year
- 1.85
- Follow on index
- 0.43
- Investments by industry
- Health Care (28)
- Biotechnology (27)
- Pharmaceutical (16)
- Medical (13)
- Medical Device (10) Show 14 more
- Investments by region
-
- United States (27)
- Switzerland (6)
- Germany (2)
- Israel (2)
- Peak activity year
- 2005
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Avg. valuation at time of investment
- 84M
- Group Appearance index
- 0.89
- Avg. company exit year
- 11
- Avg. multiplicator
- 2.17
- Strategy success index
- 0.20
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| ACT Biotech | 06 May 2008 | Biotechnology, Health Care, Medical | Early Stage Venture | 6M | United States, California, San Francisco |
| Santhera Pharmaceuticals | 20 Dec 2005 | Biotechnology, Health Care, Pharmaceutical | Early Stage Venture | 18M | Switzerland, Basel-Country |
| Turing College | 06 Sep 2021 | EdTech, Higher Education, Education | Seed | 1M | United States, Delaware, Wilmington |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.